Histogen IncOver The Counter Market:HSTO
- LAST PRICE0.1501
- TODAY'S CHANGE (%)-0.3499 (-69.9800%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0501 / 0.5000
- Day Range
- 52 Week Range
- Volume955
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HSTO |
|---|---|---|
| 09:32 ET | 100 | 0.0501 |
| 10:17 ET | 150 | 0.1001 |
| 10:24 ET | 100 | 0.1001 |
| 01:55 ET | 250 | 0.1501 |
Yesterday
Press Release: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering, from 6:02PM ET on Thursday Apr 18, 2024 by Dow Jones
6:02PM ET on Thursday Apr 18, 2024 by Dow JonesHistogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering, from 5:29PM ET on Thursday Apr 18, 2024 by Dow Jones
5:29PM ET on Thursday Apr 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Histogen Inc | 2.1M | -0.1x | --- |
InMed Pharmaceuticals Inc | 1.8M | -0.2x | --- |
Aridis Pharmaceuticals Inc | 2.7M | -0.3x | --- |
Antigenics Inc | 2.4K | 0.0x | --- |
Rayont Inc | 25.1K | 0.0x | --- |
Trevena Inc | 6.7M | -0.1x | --- |
Company Information
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Contact Information
- Headquarters
- 10655 SORRENTO VALLEY ROAD, SUITE 200SAN DIEGO, CA, United States 92121
- Phone
- 858-526-3100
- Fax
- 302-636-5454
Executives
- Non-Executive Chairman of the Board
- Daniel Kisner
- President, Chief Executive Officer, Chief Financial Officer
- Susan Knudson
- Independent Director
- David Crean
- Independent Director
- Rochelle Fuhrmann
- Independent Director
- Jonathan Jackson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1M |
|---|---|
Revenue (TTM) | $19.0K |
Shares Outstanding | 4.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-2.90 |
Book Value | $3.37 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 112.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -63,442.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
